Home / Resource Library / Tisagenlecleucel Vs Standard of Care As Second Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Tisagenlecleucel Vs Standard of Care As Second Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study